FY2025 Earnings Forecast for LRMR Issued By Lifesci Capital

Larimar Therapeutics, Inc. (NASDAQ:LRMR - Free Report) - Lifesci Capital issued their FY2025 EPS estimates for shares of Larimar Therapeutics in a report issued on Monday, June 23rd. Lifesci Capital analyst C. Jubinville expects that the company will post earnings of ($1.84) per share for the year. The consensus estimate for Larimar Therapeutics' current full-year earnings is ($1.15) per share.

Larimar Therapeutics (NASDAQ:LRMR - Get Free Report) last released its quarterly earnings results on Wednesday, April 30th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.04).

LRMR has been the subject of a number of other reports. HC Wainwright increased their price target on shares of Larimar Therapeutics from $15.00 to $16.00 and gave the stock a "buy" rating in a research note on Tuesday, March 25th. Guggenheim reissued a "buy" rating and issued a $26.00 price target on shares of Larimar Therapeutics in a research note on Tuesday, June 24th. Wedbush decreased their price target on shares of Larimar Therapeutics from $17.00 to $15.00 and set an "outperform" rating for the company in a research note on Tuesday, June 24th. Citigroup reissued a "buy" rating on shares of Larimar Therapeutics in a research note on Tuesday, June 24th. Finally, Robert W. Baird decreased their price target on shares of Larimar Therapeutics from $13.00 to $10.00 and set an "outperform" rating for the company in a research note on Tuesday, March 25th. Eight investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Larimar Therapeutics currently has a consensus rating of "Buy" and an average target price of $18.50.

Larimar Therapeutics Price Performance

LRMR stock traded down $0.05 during trading on Thursday, reaching $3.03. The company had a trading volume of 1,913,731 shares, compared to its average volume of 836,795. Larimar Therapeutics has a 52 week low of $1.61 and a 52 week high of $11.20. The company has a market cap of $194.01 million, a P/E ratio of -2.03 and a beta of 0.79. The business has a 50 day moving average of $2.41 and a 200 day moving average of $2.86.

Hedge Funds Weigh In On Larimar Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Fi3 FINANCIAL ADVISORS LLC increased its stake in shares of Larimar Therapeutics by 16.7% during the fourth quarter. Fi3 FINANCIAL ADVISORS LLC now owns 23,798 shares of the company's stock valued at $92,000 after purchasing an additional 3,411 shares in the last quarter. Envestnet Asset Management Inc. grew its holdings in shares of Larimar Therapeutics by 12.3% during the fourth quarter. Envestnet Asset Management Inc. now owns 35,525 shares of the company's stock valued at $137,000 after buying an additional 3,877 shares during the last quarter. Bank of America Corp DE grew its holdings in shares of Larimar Therapeutics by 8.1% during the fourth quarter. Bank of America Corp DE now owns 53,190 shares of the company's stock valued at $206,000 after buying an additional 3,980 shares during the last quarter. BNP Paribas Financial Markets purchased a new stake in shares of Larimar Therapeutics during the fourth quarter valued at approximately $25,000. Finally, Wells Fargo & Company MN grew its holdings in shares of Larimar Therapeutics by 51.7% during the fourth quarter. Wells Fargo & Company MN now owns 19,657 shares of the company's stock valued at $76,000 after buying an additional 6,701 shares during the last quarter. Institutional investors own 91.92% of the company's stock.

About Larimar Therapeutics

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.